P09-14. Emergence of b12 resistant rapidly replication HIV-1 variants during natural infection in the absence of humoral or cellular immune pressure by Schuitemaker H, van Nuenen A, Pisas L, Lobbrecht M, Bunnik E

Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum. by van Gils, M, Edo-Matas, D, Bowles, E, Burger, J, Stewart-Jones, G, Schuitemaker, H

A new classification for HIV-1. by Berger, E, Doms, R, Fenyö, E, Korber, B, Littman, DR, Moore, J, Sattentau, Q, Schuitemaker, H, Sodroski, J, Weiss, R

Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells. by Vyakarnam, A, Eyeson, J, Teo, I, Zuckerman, M, Babaahmady, K, Schuitemaker, H, Shaunak, S, Rostron, T, Rowland-Jones, S, Simmons, G, Clapham, P

OA06-05. Adaptation of HIV-1 to the human immune system at the population level is driven by protective HLA-B alleles by Schuitemaker H, Kesmir C, Miedema F, Kootstra N, Berkhout B, Boeser-Nunnink B, van Deutekom HW, Navis M, Schellens IM, van Baarle D, Borghans JA

Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in t... by Edo-Matas, D, van Gils, M, Bowles, E, Navis, M, Rachinger, A, Boeser-Nunnink, B, Stewart-Jones, G, Kootstra, N, van 't Wout, AB, Schuitemaker, H

Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization by Heyndrickx L, Stewart-Jones G, Schuitemaker H, Bowles E, Buonaguro L, Jansson M, Grevstad B, Vinner L, Ramaswamy M, Biswas P, Scarlatti G, Vanham G, Fomsgaard A

HIV-1 Subtype C gag-specific T-cell responses in relation to human leukocyte antigens in a diverse population of HIV-infected Ethiopians. by Tsegaye, A, Ran, L, Wolday, D, Petros, B, Dorigo, W, Piriou, E, Messele, T, Sanders, E, Tilahun, T, Eshetu, D, Schuitemaker, H, Coutinho, R, Miedema, F, Borghans, J, van Baarle, D

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group by Polonis V, Osmanov S, Morris L, Moog C, Montefiori D, Malnati M, Lopalco L, Jansson M, Holmes H, Heyndrickx L, Heath A, Fenyö E, Bongertz V, Alcami J, Scarlatti G, Ramaswamy M, Sattentau Q, Schuitemaker H, Wrin T

Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group by Scarlatti, G, Alcami, J, Bongertz, V, Fenyo, E, Heath, A, Heyndrickx, L, Holmes, H, Jansson, M, Lopalco, L, Malnati, M, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Ramaswamy, M, Sattentau, Q, Schuitemaker, H, Wrin, T

P19-08. Immunisation with recombinant HLA class I and II, HIV-1gp140 and SIVp27 antigens elicits protection against SHIV-SF162P4 infection in rhesus macaques by Schuitemaker H, Wyatt RT, Shao Y, Yang G, Vaughan R, Singh M, Bergmeier LA, Wang Y, Seidl T, Shaw O, Pihlainen E, Bergqvist L, Wehlin L, Bunnik E, Jansson M, Schøller J, Mörner A, Biberfeld G, Thorstensson R, Lehner T

Standardization of HIV Neutralization Assays for Use in Vaccine Research and Clinical Trials: Results from the NeutNet Working Group by Scarlatti, G, Alcami, J, Bongertz, V, Dispinseri, S, Donners, H, Fenyo, E, Heath, A, Heyndrickx, L, Holmes, H, Jassoy, C, Lusso, P, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Sattentau, Q, Schuitemaker, H, Sutthent, R, Wrin, T, Zolla-Pazner, S

International network for comparison of HIV neutralization assays: the NeutNet report II. by Heyndrickx, L, Heath, A, Sheik-Khalil, E, Alcami, J, Bongertz, V, Jansson, M, Malnati, M, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Ramaswamy, M, Sattentau, Q, Tolazzi, M, Schuitemaker, H, Willems, B, Wrin, T, Fenyo, E, Scarlatti, G

International network for comparison of HIV neutralization assays: the NeutNet report. by Fenyo, E, Heath, A, Dispinseri, S, Holmes, H, Lusso, P, Zolla-Pazner, S, Donners, H, Heyndrickx, L, Alcami, J, Bongertz, V, Jassoy, C, Malnati, M, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Sattentau, Q, Schuitemaker, H, Sutthent, R, Wrin, T, Scarlatti, G

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. by van Gils, M, van den Kerkhof, T, Ozorowski, G, Cottrell, C, Sok, D, Pauthner, M, Pallesen, J, de Val, N, Yasmeen, A, de Taeye, S, Schorcht, A, Gumbs, S, Johanna, I, Saye-Francisco, K, Liang, C, Landais, E, Nie, X, Pritchard, L, Crispin, M, Kelsoe, G, Wilson, I, Schuitemaker, H, Klasse, P, Moore, J, Burton, D, Ward, A, Sanders, R

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. by de Taeye, S, Ozorowski, G, Torrents de la Peña, A, Guttman, M, Julien, J, van den Kerkhof, T, Burger, J, Pritchard, L, Pugach, P, Yasmeen, A, Crampton, J, Hu, J, Bontjer, I, Torres, J, Arendt, H, DeStefano, J, Koff, W, Schuitemaker, H, Eggink, D, Berkhout, B, Dean, H, LaBranche, C, Crotty, S, Crispin, M, Montefiori, D, Klasse, P, Lee, K, Moore, J, Wilson, I, Ward, A, Sanders, R

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial by Milligan, I, Gibani, M, Sewell, R, Clutterbuck, E, Campbell, D, Plested, E, Nuthall, E, Voysey, M, Silva-Reyes, L, McElrath, M, De Rosa, S, Frahm, N, Cohen, K, Shukarev, G, Orzabal, N, van Duijnhoven, W, Truyers, C, Bachmayer, N, Splinter, D, Samy, N, Pau, M, Schuitemaker, H, Luhn, K, Callendret, B, Van Hoof, J, Douoguih, M, Ewer, K, Angus, B, Pollard, A, Snape, M

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial by Milligan, I, Gibani, M, Sewell, R, Clutterbuck, E, Campbell, D, Plested, E, Nuthall, E, Voysey, M, Silva Reyes, L, McElrath, M, De Rosa, S, Frahm, N, Cohen, K, Shukarev, G, Orzabal, N, van Duijnhoven, W, Truyers, C, Bachmayer, N, Splinter, D, Samy, N, Grazia Pau, M, Schuitemaker, H, Luhn, K, Callendret, B, Van Hoof, J, Douoguih, M, Ewer, K, Angus, B, Pollard, A, Snape, M